Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial

作者：Yang He, Nianrong Mi, Zhifeng Cheng, Haibo Xue, Jie Han, Haifang Wang, Huihui Wang, Jun Wu, Xiaoguang Shi, Shuping Zhao, Binhong Duan, Yikun Zhu, Zhou Yanqin, Feng Li, Xin Wang, Hongwei Ling, Su Wang, Qingju Li, Feifei Jiang, Ming Yang, SHAOHUI BING, Qing Zheng, Jing Ning, Mengying Guo, Yue Bu, Lei Guan, Yao Li, Liu Yang, Wanjun Guo, Hongbo Pan, Xiaoying Li · 发表于：The Lancet Diabetes & Endocrinology · 年份：2025 · DOI：10.1016/s2213-8587(25)00196-2 · 被引用次数：9 · 研究领域：Diabetes Treatment and Management、Receptor Mechanisms and Signaling、Pancreatic function and diabetes